Educational information for adults 21+. This article is not medical advice. Kiody does not sell concentrated 7-OH.
Important safety note
This guide is educational. It does not diagnose a pregnancy
complication, determine whether an exposure harmed a baby, recommend a
taper or replace prenatal, emergency, pediatric or lactation care.
If a pregnant or breastfeeding adult has collapsed, is having a
seizure, has trouble breathing or cannot be awakened, call 911
immediately. If an infant has breathing difficulty, unusual
limpness, a seizure, blue or gray coloring or cannot be awakened
normally, call 911 immediately.
For a possible poisoning in the United States, call Poison
Help at 1-800-222-1222. Poison specialists can give
case-specific instructions. Do not intentionally cause vomiting or
depend on an online dosing formula.
If kratom has been used regularly during pregnancy, tell the prenatal
and delivery teams. Do not use this page to design a sudden stop, taper,
substitution or medication plan. NIDA reports that some adults
experience withdrawal after regular kratom use, while pregnancy adds
clinical considerations that require individualized care.
Kiody serves adults age 21 and older. Kiody does not sell
concentrated 7-hydroxymitragynine (7-OH) products.
The short answer
Kratom has not been established as safe during pregnancy or
breastfeeding. Human pregnancy data are sparse, controlled safety trials
are not available and product composition varies. NIDA reports at least
five published cases of opioid-like neonatal abstinence syndrome in
infants born to women who regularly used kratom without reported opioid
use. Those cases are important safety signals, but they do not reveal
how often the outcome occurs or provide a universal dose threshold.
For breastfeeding, the National Library of Medicine’s LactMed
database reported in its December 15, 2025 revision that it found no
relevant published measurements of kratom compounds in maternal milk or
infant blood. LactMed states that nursing mothers should generally avoid
kratom because the infant effects of exposure to multiple
central-nervous-system-active substances in milk are unknown.
The useful next step is not to search for a supposedly safe strain,
color, serving or waiting period. It is to give a qualified clinician an
accurate, nonjudgmental account of:
- The exact product and brand
- Whether it is plain leaf, an extract, enhanced material or a
concentrated 7-OH product - The label ingredients and claimed alkaloid content
- How much and how often it has been used
- When it was last used
- Other medicines, supplements, alcohol or substances involved
- Whether skipping or reducing use causes symptoms
- Pregnancy stage, delivery timing or breastfeeding status
- Any symptoms in the adult or infant
An adult who already used kratom before realizing she was pregnant
should not assume that harm occurred. She also should not interpret the
lack of immediate symptoms as proof of safety. A clinician can review
the exposure in context and decide what follow-up is appropriate.
Why the evidence
requires careful wording
Questions about pregnancy often invite a simple yes-or-no answer.
Kratom research does not support one based on a precise dose, trimester,
strain or product format.
Three facts can be true at the same time:
- Evidence is limited. Very little research has
examined kratom before, during or after pregnancy. - Limited evidence is not evidence of safety. The
absence of large studies cannot establish that exposure is
harmless. - Published newborn withdrawal cases matter but have
limits. Case reports can alert clinicians to a possible
problem. They cannot calculate incidence, prove that every reported
symptom came from kratom or identify a safe exposure level.
NIDA notes that many pregnancy cases may involve other substances,
which makes the effects of kratom alone difficult to isolate. Product
contamination, inaccurate labeling, dose uncertainty and differences
among leaf, extracts and concentrated alkaloid products add more
uncertainty.
A responsible article should therefore avoid both extremes. It should
not claim that all exposure causes a particular outcome. It also should
not reassure readers that botanical origin, traditional use or a small
serving proves safety.
Pregnancy,
newborn withdrawal and breastfeeding are different questions
These topics are related, but they should not be collapsed into one
risk statement.
Exposure during pregnancy
Pregnancy exposure concerns what reaches or affects the developing
fetus while a product is used before delivery. Direct human data on
kratom compounds, placental transfer, trimester-specific effects and
dose-response relationships are inadequate. That means a website cannot
responsibly publish a safe trimester, safe frequency or safe alkaloid
limit.
Newborn withdrawal after
delivery
Neonatal abstinence syndrome, or NAS, is a collection of withdrawal
signs that can occur after prenatal exposure to certain substances ends
at birth. NIDA reports opioid-like NAS in at least five infants whose
mothers regularly used kratom without opioids. A baby experiences
withdrawal; a baby is not “born addicted.” Addiction is a behavioral
disorder and is not the correct description for an infant.
The published cases do not show that every infant exposed to kratom
will develop withdrawal. They do show why prenatal and delivery teams
need an accurate exposure history. Advance knowledge can affect
observation and clinical evaluation after birth.
Exposure during
breastfeeding
Breastfeeding asks whether kratom compounds or other product
constituents enter milk, at what levels, how an infant absorbs them and
what effects may occur. LactMed found no relevant published maternal or
infant concentration data as of its December 2025 review. It therefore
does not provide a validated “pump and dump” interval, safe waiting time
or safe maternal serving.
Breastfeeding should not be presented as a home treatment for
suspected newborn withdrawal. LactMed describes mixed details from a few
cases, and an infant with possible withdrawal needs direct pediatric
evaluation.
What NIDA says about
kratom and pregnancy
The National Institute on Drug Abuse summarizes the current evidence
in restrained terms:
- Very little research is available on kratom use before, during and
after pregnancy. - Pregnancy reports often include other substances, making
kratom-specific effects difficult to determine. - A 2021 review identified at least five cases of opioid-like NAS
after regular maternal kratom use without reported opioid use. - The infants in those reports responded to standard treatment used
for opioid-related NAS.
This summary does not establish a safe dose or recommend kratom as a
treatment. NIDA separately states that kratom has not been proven safe
and effective for any medical purpose and that no medical therapies are
currently approved specifically for kratom withdrawal or kratom-related
substance use disorder.
Those distinctions are important. “A case was treated successfully”
does not mean an exposure is safe. “Research is limited” does not mean
no risk exists. “No approved kratom-withdrawal medicine” does not mean a
clinician has no way to help; it means treatment decisions require
professional assessment rather than a standardized kratom-specific
product claim.
What LactMed says about
breastfeeding
LactMed is a National Library of Medicine database designed to
summarize evidence about substances and lactation. Its kratom entry was
last revised December 15, 2025.
The entry reports:
- Published measurements of kratom levels in maternal milk were not
found. - Published measurements of levels in breastfed infants were not
found. - Relevant evidence about kratom’s effects on lactation and milk
production was not found. - Newborn withdrawal has been described after regular use during
pregnancy. - Nursing mothers should generally avoid kratom because infant effects
are unknown.
This does not support converting an adult half-life estimate into a
breastfeeding interval. Milk transfer and infant exposure depend on more
than the time a compound remains in adult blood. The product may contain
multiple alkaloids, an extract may differ from leaf and an infant’s
ability to process substances differs from an adult’s.
It also does not support assuming that a product marketed as
“natural,” “tea,” “low dose” or “lab tested” is compatible with
breastfeeding. Testing can answer specified identity, potency or
contaminant questions. It cannot create pregnancy or lactation safety
evidence that does not exist.
Botanical
leaf is not the same as concentrated 7-OH
Product distinctions matter when documenting an exposure, but none of
these categories has an established pregnancy-safe or breastfeeding-safe
serving.
Plain botanical leaf
This category includes dried leaf, powder, brewed leaf tea and
capsules filled only with leaf powder. Kiody capsules contain
approximately 500 milligrams of pure botanical leaf per capsule. That
number describes approximate capsule fill weight—not a proven safe
amount, an alkaloid measurement or a pregnancy recommendation.
Leaf naturally contains a mixture of alkaloids. The composition can
differ among lots. A color or strain-style name does not establish
chemical composition or pregnancy safety.
Extracts
Extracts concentrate selected plant constituents. They may be
liquids, powders, gummies, tablets or capsules. Labels may describe a
ratio, percentage, total alkaloids or milligrams per serving. Those
measures are not interchangeable, and a package format does not reveal
strength.
Enhanced products
Enhanced leaf has an extract, isolate or other concentrate added to
botanical material. It may look similar to ordinary powder. “Enhanced”
should be disclosed to a clinician even when the label does not quantify
every added constituent.
Added or concentrated 7-OH
FDA distinguishes trace 7-OH naturally present in leaf from products
containing added or enhanced 7-OH. FDA describes the latter as novel
potent opioid products and advises consumers to avoid them. Tablets,
gummies, shots, drink mixes and other concentrated formats should not be
assumed equivalent to plain leaf.
Kiody does not sell concentrated 7-OH products.
Manufactured derivatives
Mitragynine pseudoindoxyl (MGPI), MGM-15 and MGM-16 are distinct
compounds, not interchangeable names for ordinary leaf. DEA temporarily
placed these three substances in federal Schedule I effective August 26,
2026. Product names such as “pseudo,” “advanced alkaloid” or “next
generation” should be copied exactly for a clinician, pharmacist or
poison specialist.
Multi-ingredient products
A product can include kratom plus caffeine, cannabinoids, kava,
sedating ingredients, stimulants, medications or undeclared substances.
A prenatal risk assessment needs the complete ingredient panel and, when
available, the package itself. Do not report only the word “kratom” if
the product contains more.
What the
published reports can and cannot tell readers
Case reports are valuable because unusual events may first become
visible through individual clinical observations. But they have
structural limits.
They can:
- Describe the adult’s reported pattern of use
- Record signs clinicians observed in a newborn
- Document testing and treatment decisions
- Suggest questions for future research
- Alert delivery teams to consider an exposure history
They generally cannot:
- Calculate how common an outcome is
- Establish a minimum harmful dose
- Establish a maximum safe dose
- Separate every effect of kratom from other products or health
conditions - Confirm the exact composition of every product used
- Compare leaf reliably with all extracts or concentrated 7-OH
products - Predict an individual infant’s outcome
- Establish long-term developmental effects
This is why Kiody should not turn a handful of cases into a dramatic
universal claim. It is also why marketing language such as “no reports
at this amount” would be misleading. Without systematic exposure and
outcome data, missing reports do not prove safety.
If kratom
was used before pregnancy was recognized
Unexpected exposure is a common reason people search this topic. The
useful response is organized disclosure, not panic or concealment.
- Do not assume an outcome. A webpage cannot
determine whether an individual pregnancy was affected. - Record the dates. Estimate the first and last use
dates and when pregnancy was recognized. - Identify the product. Photograph the front, back,
ingredient panel, lot number and any strength statement. - Describe use honestly. Record amount, frequency,
method and any recent change. - List everything else. Include prescriptions,
over-the-counter medicines, supplements, nicotine, alcohol and other
substances. - Contact the prenatal clinician. Ask what
information and follow-up the clinician needs. - Mention dependence concerns. Report symptoms that
occur when use is delayed or stopped. - Seek urgent help for acute symptoms. Use 911 or
Poison Help when appropriate.
Do not replace the original product with a “detox,” concentrated
extract, 7-OH product or unlabeled substitute. Do not use an internet
taper designed for another person. Pregnancy changes the balance of
risks and requires individualized clinical guidance.
A 12-step clinician
conversation plan
The goal is to make a short appointment more useful and reduce
avoidable uncertainty.
1. Bring the package
Bring the original container if it is safe to do so. Otherwise bring
clear photographs. Include outer packaging, inner packets, tablets,
droppers and inserts.
2. State the product category
Say whether it appears to be leaf, pure-leaf capsules, extract,
enhanced powder, concentrated 7-OH or an unknown formulation. If unsure,
say that clearly.
3. State
the labeled strength without translating it
Copy “10:1,” “45% total alkaloids,” “20 mg mitragynine” or “15 mg
7-OH” exactly as written. Do not convert a ratio into milligrams without
validated product-specific data.
4. Describe actual use
Include approximate grams, capsule count, tablet count, milliliters
or package fraction. State frequency and duration. An approximate honest
record is more useful than false precision.
5. Give timing
Record the most recent use and the usual time between uses. Note any
exposure after delivery while breastfeeding.
6. List other substances
Include medicines and supplements even when they seem unrelated.
Multiple substances can change clinical interpretation.
7. Explain the reason for use
Some adults report using kratom for pain, mood, energy or to manage
withdrawal. This is not proof of efficacy, but the clinician needs to
understand what problem may reappear if use changes.
8. Describe symptoms between
uses
Report restlessness, stomach symptoms, sweating, sleep problems,
irritability or other changes without diagnosing them yourself. Note
timing and severity.
9. Describe current
pregnancy symptoms
Report vomiting, dehydration, bleeding, reduced fetal movement when
applicable or any symptom the prenatal team has asked you to monitor.
Follow the team’s urgent-care instructions.
10. Ask about delivery
planning
If use continued later in pregnancy, ask what the delivery hospital
and newborn team should know and whether observation plans need to
change.
11. Ask about
breastfeeding separately
Do not assume a pregnancy answer automatically resolves milk
exposure. Ask the obstetric, pediatric and lactation teams to
coordinate.
12. Write down the plan
Record whom to call, what symptoms require urgent care, follow-up
dates and how medication or substance changes should be managed. Confirm
rather than relying on memory.
Planning for
delivery and newborn observation
A delivery team cannot act on an exposure it does not know about.
Regular use, especially later in pregnancy, should be disclosed before
delivery when possible.
NIDA’s general pregnancy guidance explains that newborn withdrawal
signs can include excessive or high-pitched crying, feeding difficulty,
vomiting, diarrhea, tremors, increased muscle tone, irritability, sleep
problems, rapid breathing, sweating and seizures. This list is not a
home diagnostic checklist and is not specific enough to prove kratom
withdrawal. Newborn infections, metabolic problems and other medical
conditions can produce overlapping signs.
Parents and caregivers should:
- Tell the newborn team about the product and use pattern
- Avoid minimizing an extract as “just tea”
- Bring product photographs or packaging
- Ask how long the baby needs observation
- Ask which signs require immediate staff attention
- Keep all adult products out of the hospital bassinet, diaper bag and
feeding area - Avoid giving any kratom product directly to an infant
Do not attempt to treat a newborn by adding botanical products to a
bottle, applying them to a pacifier or changing breastfeeding solely to
alter withdrawal signs. The baby’s care belongs with the pediatric
team.
Breastfeeding
decisions need coordinated care
Breastfeeding provides important benefits for most infants, but
exposure questions require case-specific risk assessment. CDC notes that
clinicians should make case-by-case decisions when a maternal exposure
or medical condition may affect breastfeeding. LactMed provides the more
substance-specific point: information on kratom in milk and exposed
infants is sparse, and nursing mothers should generally avoid it.
Questions for the care team include:
- Is the infant premature or medically fragile?
- Was there regular prenatal exposure?
- Is the infant being observed or treated for withdrawal?
- What exact product was used after delivery?
- Are other sedating or stimulating substances involved?
- What feeding alternatives are available if breastfeeding is
interrupted? - How can milk production be supported if a temporary interruption is
advised? - Who decides when breastfeeding can begin or resume?
- What infant signs require urgent evaluation?
No published evidence supports a universal number of hours to wait
after kratom. “Pump and dump once” is not an evidence-based rule for
this substance. Neither is calculating an interval from adult effects
alone.
Why “lab
tested” does not answer pregnancy safety
A legitimate certificate of analysis may help identify a lot and
report particular measurements. Depending on the panel, it may
address:
- Mitragynine and 7-OH concentration
- Microbial contaminants
- Heavy metals
- Selected pesticides
- Mycotoxins
- Residual solvents
- Identity or adulteration screens
But a COA ordinarily does not establish:
- Safety during pregnancy
- Placental transfer
- Effects on fetal development
- Transfer into human milk
- Infant absorption or metabolism
- A safe pregnancy or breastfeeding serving
- Safety of combining the product with medicines
A test result also represents the submitted sample, not automatically
every package in the market. The lot number, sample chain of custody and
method scope still matter.
Marketing statements to
distrust
Treat these statements as warning signs rather than evidence:
- “Safe because it is natural.”
- “Traditional use proves pregnancy safety.”
- “Plain leaf cannot affect a newborn.”
- “One capsule is always safe.”
- “Red strains are safe for pregnancy.”
- “White strains are too mild to matter.”
- “A low ratio means no fetal exposure.”
- “Lab tested means pregnancy approved.”
- “FDA registered means FDA approved.”
- “GMP certified means tested in pregnant women.”
- “No warning on the package means no risk.”
- “A negative routine drug screen proves no exposure.”
- “Breast milk filters out botanical alkaloids.”
- “Waiting until you feel normal makes milk safe.”
- “Pumping once clears everything.”
- “Breastfeeding is a home treatment for newborn withdrawal.”
- “7-OH is simply stronger leaf.”
- “A tiny tablet must contain a tiny amount.”
- “Withdrawal means the baby is addicted.”
- “Stopping suddenly is always the safest choice.”
The last statement is especially important. A webpage should not
instruct a pregnant adult who uses regularly to continue or stop
abruptly. It should direct her to prompt medical assessment.
Five realistic
questions and responsible answers
Scenario
1: A few capsules before a positive pregnancy test
An adult used two pure-leaf capsules on several days before realizing
she was pregnant. She has no symptoms and wants a guarantee.
Responsible response: Do not promise that harm did
or did not occur. Record the product, dates, approximate amount and
other exposures, then discuss them with the prenatal clinician. One
limited exposure is not equivalent to the regular use described in
published newborn-withdrawal cases, but that difference does not create
a guaranteed safe dose.
Scenario 2: Daily
powder use late in pregnancy
An adult reports daily powder use and feels unwell when she skips it.
Delivery is approaching.
Responsible response: Encourage prompt disclosure to
the prenatal and delivery teams. Do not provide a website taper. The
team needs the use pattern, last-use time, other substances and product
packaging to plan maternal and newborn care.
Scenario 3: An unlabeled
extract
The product is a small liquid bottle with no readable ingredient or
alkaloid information.
Responsible response: Treat composition as unknown.
Bring the bottle or photos, note how much may have been used and contact
the clinician or Poison Help as appropriate. Do not infer strength from
bottle size, taste or retail location.
Scenario 4:
Breastfeeding after occasional leaf tea
The parent asks how many hours to wait before nursing.
Responsible response: No validated universal waiting
interval exists. LactMed found no relevant milk or infant level data and
says nursing mothers should generally avoid kratom. Contact the
pediatric and maternal care teams for a feeding plan tailored to the
infant and exposure.
Scenario 5:
A product marketed as concentrated 7-OH
The package contains pressed tablets labeled with milligrams of
7-OH.
Responsible response: Do not treat it as ordinary
leaf. FDA advises consumers to avoid added or enhanced 7-OH products.
Give the exact milligrams, serving language, ingredients, use time and
package to the clinician or poison specialist.
A record to prepare for
the care team
Copy this worksheet into a private note. Do not post personal medical
information publicly.
Person and timing
- Date prepared:
- Estimated gestational age or postpartum date:
- Prenatal clinician:
- Delivery facility:
- Pediatric clinician:
- Lactation consultant, if any:
- Emergency contact:
Product identity
- Brand:
- Exact product name:
- Form: leaf / powder / capsule / tea / extract / gummy / tablet /
liquid / unknown - Plain leaf, enhanced, 7-OH or unknown:
- Ingredient list:
- Labeled serving:
- Mitragynine statement:
- 7-OH statement:
- Extract ratio or total-alkaloid statement:
- Other active ingredients:
- Lot or batch number:
- Best-by date:
- Purchase source and date:
- Package and photographs retained: yes / no
- COA available: yes / no
Use history
- First date used:
- Most recent date and time:
- Typical amount:
- Highest recent amount:
- Frequency:
- Route or preparation:
- Duration of regular use:
- Reason reported for use:
- Recent increase, decrease or product change:
- Symptoms when delayed or stopped:
- Prior attempt to stop or reduce:
Other exposures
- Prescription medicines:
- Over-the-counter medicines:
- Vitamins and supplements:
- Nicotine:
- Alcohol:
- Cannabis:
- Other substances:
- Caffeine or energy products:
Current concerns
- Adult symptoms:
- Pregnancy concerns:
- Infant symptoms:
- Feeding method:
- Calls already made:
- Instructions received:
- Follow-up appointment:
- Questions still unanswered:
This record improves communication. It does not replace the
clinician’s history, examination or testing.
Frequently asked questions
Is kratom safe during
pregnancy?
Safety has not been established. Human evidence is limited, and
reports of newborn withdrawal after regular maternal use exist. Discuss
any exposure with a prenatal clinician.
Is there a safe
amount of kratom while pregnant?
No authoritative source has established a universally safe serving,
frequency or alkaloid level for pregnancy.
Is occasional use
different from daily use?
Frequency and duration are relevant to clinical assessment, but
available evidence does not define a safe occasional-use threshold.
Report the actual pattern rather than relying on a category.
Does the trimester change
the answer?
Pregnancy stage is important information for a clinician, but
research does not provide a kratom-safe trimester.
What if I
used kratom before I knew I was pregnant?
Do not assume that an adverse outcome occurred. Record the exposure
and discuss it with prenatal care. Seek urgent help for serious
symptoms.
Should I
stop immediately after a positive pregnancy test?
Do not use a webpage to make an abrupt change if use has been regular
or stopping produces symptoms. Contact a prenatal clinician promptly for
an individualized plan.
Can kratom
cause a newborn to experience withdrawal?
NIDA reports at least five cases of opioid-like NAS in infants after
regular maternal kratom use without reported opioid use. Case reports do
not establish how often this occurs or a dose threshold.
Is newborn
withdrawal the same as addiction?
No. Withdrawal is a physiological response after exposure ends.
Addiction is a behavioral disorder and is not an appropriate label for a
newborn.
What should the delivery
team know?
Tell them the product, category, strength statements, amount,
frequency, last-use time, duration, other substances and any symptoms
between uses.
Can a routine drug test
detect kratom?
Many routine panels do not specifically test for kratom alkaloids,
while specialized testing may. A negative routine result does not prove
there was no exposure. Do not withhold history because a screen is
negative.
Is
plain leaf safer than concentrated 7-OH during pregnancy?
They are different products and should be identified separately.
Neither has an established pregnancy-safe serving. FDA specifically
advises consumers to avoid added or enhanced 7-OH products.
Do strain colors
matter for pregnancy safety?
No strain color establishes safety. Red, green and white labels are
market categories, not pregnancy-risk classifications.
Are pure-leaf capsules
safer than powder?
Capsules can improve portion consistency, but the format does not
establish pregnancy safety. Pure-leaf capsules and loose leaf should
both be disclosed.
Does
a 500-milligram capsule contain 500 milligrams of mitragynine?
No. For Kiody’s pure-leaf capsules, approximately 500 milligrams
refers to leaf fill weight, not mitragynine or 7-OH content.
Does a
COA show that a product is safe while pregnant?
No. A COA may report specified composition or contaminant results. It
does not establish reproductive, fetal or neonatal safety.
Can kratom pass into breast
milk?
Direct published concentration data are lacking. LactMed found no
relevant maternal milk or infant level measurements and recommends that
nursing mothers generally avoid kratom because infant effects are
unknown.
How long
should I wait to breastfeed after kratom?
No validated universal interval has been established. Ask the
maternal and pediatric care teams for a case-specific feeding plan.
Does
pumping and discarding milk once eliminate exposure?
There is no evidence-based one-pump rule for kratom. Do not use an
adult effect duration as a milk-clearance calculation.
Can
breastfeeding treat newborn kratom withdrawal?
Breastfeeding should not be used as a home treatment. An infant with
possible withdrawal needs direct pediatric evaluation and a coordinated
feeding plan.
What infant signs need
emergency help?
Call 911 for breathing difficulty, a seizure, blue or gray coloring,
unusual limpness or inability to awaken normally. Contact the pediatric
team promptly for feeding problems, unusual irritability, tremors,
repeated vomiting or other concerning changes.
Can kratom
be used for pregnancy nausea, pain or mood?
Kratom is not FDA approved to diagnose, treat, cure or prevent these
conditions. A prenatal clinician can discuss options with
pregnancy-specific evidence.
Can
kratom be used to self-treat opioid withdrawal during pregnancy?
It is not an approved treatment. Opioid withdrawal and opioid use
disorder during pregnancy require qualified medical care. Do not
substitute an unstandardized kratom product for a treatment plan.
What
if the product also contains caffeine or another botanical?
Report every ingredient and amount on the label. The risk assessment
cannot be based on kratom alone when the product contains multiple
active substances.
Does legal status prove
safety?
No. Legal status, FDA marketing status, controlled-substance
scheduling and medical safety are separate questions.
Does Kiody sell concentrated
7-OH?
No. Kiody serves adults age 21 and older and does not sell
concentrated 7-OH products.
Current federal
context as of September 3, 2026
The pregnancy discussion should remain distinct from current federal
scheduling actions:
- FDA marketing and safety position: FDA states that
no kratom-containing drug, dietary supplement or conventional food is
legally marketed in the United States and warns about serious adverse
events. - Added or enhanced 7-OH: FDA advises consumers to
avoid products containing added or enhanced 7-OH and distinguishes those
products from trace 7-OH naturally present in leaf. - Pending 7-OH proceeding: The federal proceeding
concerning 7-OH above a specified threshold remains proposed, with
comments due September 10, 2026. A proposal is not a final scheduling
rule. - MGPI, MGM-15 and MGM-16: DEA’s temporary Schedule I
order for these compounds took effect August 26, 2026. Those named
derivatives are not synonyms for ordinary botanical leaf. - State and local variation: Separate state and local
rules may restrict leaf, extracts, 7-OH or delivery. Readers should use
Kiody’s current nationwide trackers and official jurisdictional
sources.
Legal status does not create a pregnancy-safe use. Medical caution
also does not by itself establish that a product is prohibited in every
jurisdiction.
Sources and further reading
- National Institute on Drug Abuse, Kratom, updated
March 11, 2026: https://nida.nih.gov/research-topics/kratom - National Library of Medicine, LactMed, Kratom,
revised December 15, 2025: https://www.ncbi.nlm.nih.gov/sites/books/NBK617437/ - National Institute on Drug Abuse, Substance Use While
Pregnant and Breastfeeding: https://nida.nih.gov/publications/research-reports/substance-use-in-women/substance-use-while-pregnant-breastfeeding - CDC, Contraindications to Breastfeeding, updated
December 8, 2025: https://www.cdc.gov/breastfeeding-special-circumstances/hcp/contraindications/index.html - FDA, FDA and Kratom: https://www.fda.gov/news-events/public-health-focus/fda-and-kratom
- FDA, Products Containing 7-OH Can Cause Serious
Harm: https://www.fda.gov/consumers/consumer-updates/products-containing-7-oh-can-cause-serious-harm - America’s Poison Centers, Poison Help: https://www.poisonhelp.org/
- FDA, MedWatch Safety Information and Adverse Event Reporting
Program: https://www.accessdata.fda.gov/scripts/medwatch/index.cfm?action=reporting.home - Federal Register, 7-Hydroxymitragynine Above a Specified
Threshold in Schedule I; Extension of Comment Period, August
26, 2026: https://www.federalregister.gov/documents/2026/08/26/2026-17409/hydroxymitragynine-above-a-specified-threshold-in-schedule-i-extension-of-comment-period - Federal Register, Temporary Placement of Mitragynine
Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I, effective
August 26, 2026: https://www.federalregister.gov/documents/2026/08/26/2026-17429/schedules-of-controlled-substances-temporary-placement-of-mitragynine-pseudoindoxyl-mgm-15-and